Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31535Editorial articleПередовая статьяEditorialClinical guidelines for the diagnosis and treatment of pulmonary hypertensionКлинические рекомендации по диагностике и лечению легочной гипертонииChazovaI EЧазоваИ Еchazova@hotmail.comAvdeevS NАвдеевС НTsarevaN AЦареваН АVolkovA VВолковА ВMartyniukT VМартынюкТ Вtrukhiniv@mail.ruNakonechnikovS NНаконечниковС НИнститут клинической кардиологии им А.Л. Мясникова ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва15092014869VOL 86, NO9 ()ТОМ 86, №9 (2014)42310042020Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31535

Pulmonary hypertension (PH) is a group of diseases characterized by progressive increases in pulmonary vascular resistance and pulmonary artery pressure, which results in right ventricular heart failure and sudden death. Based on the current version of the guidelines for PH diagnosis and treatment, adopted by the experts of the European Society of Cardiology and the European Respiratory Society in 2009, and on the data of Russian and foreign clinical trials, the Russian experts elaborated clinical guidelines for PH in 2013. The latter consider the current classifications of PH, the specific features of its pathogenesis, and its diagnostic algorithm. The section dealing with drugs for maintenance therapy discusses data on the use of oral anticoagulants, diuretics, cardiac glycosides, and oxygen therapy. PH-specific therapy includes calcium antagonists, prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. Surgical procedures for PH involve atrial septostomy, thromboendartectomy, and lung or heart-lung transplantation. A treatment algorithm is proposed for PH patients. The current medicinal approaches using specific therapy agents and their combinations offer new promises for the effective treatment of patients with PH and improve its prognosis.

Аннотация Легочная гипертония (ЛГ) - это группа заболеваний, характеризующихся прогрессирующим повышением легочного сосудистого сопротивления и давления в легочной артерии, которое приводит к развитию правожелудочковой сердечной недостаточности и преждевременной смерти пациентов. На основании современной версии рекомендаций по диагностике и лечению ЛГ, принятой экспертами Европейского общества кардиологов и Европейского респираторного общества в 2009 г., клинических данных национальных и зарубежных исследований в 2013 г. российскими экспертами разработаны клинические рекомендации по ЛГ. В них рассматриваются современные классификации ЛГ, особенности патогенеза, алгоритма диагностики ЛГ. В разделе, посвященном средствам поддерживающей терапии, обсуждаются данные о применении пероральных антикоагулянтов, диуретиков, сердечных гликозидов, оксигенотерапии. Специфическая терапия легочной артериальной гипертонии (ЛАГ) включает антагонисты кальция, простаноиды, антагонисты рецепторов эндотелина, ингибиторы фосфодиэстеразы 5-го типа. Среди методов хирургического лечения ЛГ представлены предсердная септостомия, тромбэндартерэктомия и трансплантация легких или комплекса сердце-легкие. Предлагается алгоритм лечения больных ЛАГ. Современные медикаментозные подходы с использованием препаратов специфической терапии и их комбинаций открывают новые перспективы эффективного лечения больных ЛАГ, улучшают их прогноз.

pulmonary hypertensionclinical guidelinesлегочная гипертонияклинические рекомендацииДиагностика и лечение легочной гипертензии. Российские рекомендации. Кардиоваск тер и проф 2007; 6: Приложение 2.Simonneau G., Robbins I., Beghetti M. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.Hatano S., Strasser T. World Health Organization 1975. Primary pulmonary hypertension. Geneva: WHO 1975.Simonneau G., Galieé N., Rubin L.J. et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:S5-S12.Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007; 30: 104-109.Oudiz R.J. Pulmonary hypertension associated with left-sided heart disease. Clin Chest Med 2007; 28: 233-241.Chaouat A., Bugnet A.S., Kadaoui N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194.Hoeper M.M., Mayer E., Simonneau G., Rubin L.J. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011-2020.Guidelines for the diagnosis and treatment of pulmonary hypertension. Update 2009. European society of cardiology. Eur Heart J 2009; 30: 2493-2537.D'Alonzo G.E., Barst R.J., Ayres S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.Мартынюк Т.В. Идиопатическая легочная гипертензия: клинико-патофизиологические особенности и возможности патогенетически обоснованной терапии: Автореф. дис. ... д-ра мед. наук. М 2013.Machado R., Eickelberg O., Elliott C.G. et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S32-S42.Fedullo P.F., Auger W.R., Kerr K.M., Rubin L.J. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-1472.Беленков Ю.Н., Чазова И.Е. Первичная легочная гипертензия. М: Нолидж 1991.Morrell N., Adnot S., Archer S. et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S20-S31.Hassoun P.M., Mouthon L., Barbera J.A. et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10-S19.Stewart D.J., Levy R.D., Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-469.Sztrymf B., Coulet F., Girerd B. et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008; 177: 1377-1383.Trembath R.C., Thomson J.R., Machado R.D. et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325-334.Tongers J., Schwerdtfeger B., Klein G. et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153: 127-132.Fisher M.R., Forfia P.R., Chamera E. et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Resp Crit Care Med 2009; 179: 615-621.Mukerjee D., St George D., Knight C. et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004; 43: 461-466.Hoeper M.M., Lee S.H., Voswinckel R. et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552.Tunariu N., Gibbs S.R., Win Z. et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48: 680-684.Resten A., Maitre S., Humbert M. et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. Am J Roentgenol 2004; 183: 65-70.Torbicki A. Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. Eur Heart J 2007; 28: 1187-1189.Rich S., Kieras K., Groves B., Stobo J.D., Brundage B. Antinuclear antibodies in primary pulmonary hypertension. J Am Coll Cardiol 1986; 8: 1307-1311.Chu J.W., Kao P.N., Faul J.L., Doyle R.L. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002; 122: 1668-1673.Albrecht T., Blomley M.J., Cosgrove D.O. et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-1583.McLaughlin V.V., Presberg K.W., Doyle R.L. et al. Prognosis of pulmonary arterial hypertension ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 78S-92S.Galie N., Manes A., Palazzini M. et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs 2008; 68: 1049-1066.Mereles D., Ehlken N., Kreuscher S. et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114: 1482-1489.The Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24: 761-781.Herve P., Humbert M., Sitbon O. et al. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. Clin Chest Med 2001; 22: 451-458.Fuster V., Steele P.M., Edwards W.D. et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.Weitzenblum E., Sautegeau A., Ehrhart M. et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493-498.Rich S., Seidlitz M., Dodin E. et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-792.Rich S., Dantzker D.R., Ayres S.M. et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223.Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.Sitbon O., Humbert M., Jais X. et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.Galie N., Manes A., Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003; 2: 123-137.Rubin L.J., Mendoza J., Hood M. et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-491.Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.Olschewski H., Simonneau G., Galie N. et al., for the AIR Study Group. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.Galie N., Manes A., Negro L. et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.McLaughlin V.V., Sitbon O., Badesch D.B. et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249.Galie N., Badesch B.D., Oudiz R. et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535.Tantini B., Manes A., Fiumana E. et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131-138.Ghofrani H.A., Voswinckel R., Reichenberger F. et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44: 1488-1496.Michelakis E.D., Tymchak W., Noga M. et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069.McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.Sandoval J., Gaspar J., Pulido T. et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32: 297-304.Kurzyna M., Dabrowski M., Bielecki D. et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest 2007; 131: 977-983.Rubin L.J., Hoeper M.M., Klepetko W. et al. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc 2006; 3: 601-607.Orens J.B., Estenne M., Arcasoy S. et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755.Trulock E.P., Edwards L.B., Taylor D.O. et al. International Society for Heart and Lung Transplantation. Registry of the International Society for Heart and Lung Transplantation: twenty third official adult lung and heart lung transplantation report - 2006. J Heart Lung Transplant 2006; 25: 880-892.Barst R.J., Gibbs J.S., Ghofrani H.A. et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-S84.